Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Replimune Group (REPL – Research Report) and Verve Therapeutics (VERV – Research Report).
Replimune Group (REPL)
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Replimune Group on August 16 and set a price target of $42.00. The company’s shares closed last Thursday at $19.08.
According to TipRanks.com, Rama is a 4-star analyst with an average return of
Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $54.13, which is a 189.5% upside from current levels. In a report issued on August 2, Jefferies also maintained a Buy rating on the stock with a $49.00 price target.
See today’s best-performing stocks on TipRanks >>
Verve Therapeutics (VERV)
In a report issued on August 14, Eric Joseph from J.P. Morgan maintained a Hold rating on Verve Therapeutics, with a price target of $32.00. The company’s shares closed last Thursday at $14.57, close to its 52-week low of $13.01.
According to TipRanks.com, Joseph is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verve Therapeutics with a $43.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REPL:
- Replimune Group price target lowered to $50 from $51 at H.C. Wainwright
- Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
- Replimune Group expects cash to fund operations into 2H25
- Replimune Group reports Q1 EPS (75c), consensus (85c)
- REPL Upcoming Earnings Report: What to Expect?
